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INTRODUCTION
Urothelial cell carcinoma (UCC) of the bladder is the fifth
commonest cancer, with 357,000 new cases diagnosed yearly on a
world-wide basis (Parkin et al., 2005). The majority (75%) of these
tumors are noninvasive and well differentiated, and can be
controlled by transurethral resection of the tumor lesions. However,
up to 70% of the patients with a superficial UCC will have
recurrences after its removal, and 10-15% will progress to invasive
UCC (http://info.cancerresearchuk.org/cancerstats/). Even in cases
of no progression, regular surveillance by cystoscopy is required,
making bladder cancer one of the most expensive and labor-
intensive cancers to manage.
A number of genetic and epigenetic alterations have been
identified in bladder tumorigenesis, including activating mutations
in fibroblast growth factor receptor 3 (FGFR3) and RAS family genes,
amplification of ERBB2, and loss of the TP53, RB1 and PTEN tumor
suppressors (Schulz, 2006; Luis et al., 2007; Cordon-Cardo, 2008;
Diaz et al., 2008). Among these, somatic mutations in FGFR3 have
been identified at a high frequency in cases of superficial UCC (60-
80%) (Knowles, 2008b). FGFR3 is a receptor tyrosine kinase that is
known to mediate the effects of fibroblast growth factors (FGFs).
When these activating mutations occur in the germ line, they are
known to cause several autosomal dominant human skeletal
dysplasia syndromes (Muenke and Schell, 1995). Several studies have
shown that somatic mutations of FGFR3 are strongly associated with
bladder cancer of a low tumor grade and stage (Billerey et al., 2001;
Jebar et al., 2005; Lamy et al., 2006; Lindgren et al., 2006).
Although some previous studies strongly suggest the importance
of FGFR3 mutations in tumor formation (Chesi et al., 2001; Logie
et al., 2005), thus far they have been uninformative on the precise
mechanistic role of FGFR3 mutations in tumor formation and
progression. The role of FGF signaling in bladder cancer is not well
understood. Generation of a relevant mouse model is essential not
only for the investigation of mechanism but also for testing
potential therapeutic approaches. In this study, the role of two
potent activating mutations of FGFR3 that are found in UCC was
assessed in the initiation and development of UCC as a sole driver
in vivo, and in synergy with -catenin (Ctnnb1) and K-Ras mutations.
RESULTS
Targeting of the Fgfr3 mutations in the bladder
In order to achieve urothelium-specific conditional expression,
mice expressing Cre recombinase driven by the mouse uroplakin
II (UroII) promoter were selected. UroII is expressed throughout
the urothelial layers in mice (Mo et al., 2005). The UroIICre
promoter has been reported to successfully drive the expression of
proteins that lead to bladder tumor formation, including SV40 large
T antigen and H-Ras (Zhang et al., 2001). To demonstrate Cre-
driven recombination in the urothelium, we crossed the UroIICre+
line with Z/EG reporter mice (Novak et al., 2000). Visualization
with the Olympus OV100 whole-mouse fluorescent imaging system
showed that recombination had occurred in the urothelial lining
of the bladder, as well as in the ureters (supplementary material
Fig. S1A).
Disease Models & Mechanisms 4, 548-555 (2011) doi:10.1242/dmm.006874
1The Beatson Institute for Cancer Research, Glasgow, G61 1BD, UK
2School of Medicine, College of Medical, Veterinary and Life Sciences, University of
Glasgow, Glasgow, G12 8QQ, UK
3Department of Pharmacology, Graduate School of Medicine, Kyoto University,
Kyoto 606-8501, Japan
4Department of Urology and Pathology, New York University School of Medicine,
New York, NY 10016, USA
*Author for correspondence (o.sansom@beatson.gla.ac.uk)
Received 13 September 2010; Accepted 10 March 2011
© 2011. Published by The Company of Biologists Ltd
This is an Open Access article distributed under the terms of the Creative Commons Attribution
Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which
permits unrestricted non-commercial use, distribution and reproduction in any medium provided
that the original work is properly cited and all further distributions of the work or adaptation are
subject to the same Creative Commons License terms.
SUMMARY
The human fibroblast growth factor receptor 3 (FGFR3) gene is frequently mutated in superficial urothelial cell carcinoma (UCC). To test the functional
significance of FGFR3 activating mutations as a ‘driver’ of UCC, we targeted the expression of mutated Fgfr3 to the murine urothelium using Cre-
loxP recombination driven by the uroplakin II promoter. The introduction of the Fgfr3 mutations resulted in no obvious effect on tumorigenesis up
to 18 months of age. Furthermore, even when the Fgfr3 mutations were introduced together with K-Ras or -catenin (Ctnnb1) activating mutations,
no urothelial dysplasia or UCC was observed. Interestingly, however, owing to a sporadic ectopic Cre recombinase expression in the skin and lung
of these mice, Fgfr3 mutation caused papilloma and promoted lung tumorigenesis in cooperation with K-Ras and -catenin activation, respectively.
These results indicate that activation of FGFR3 can cooperate with other mutations to drive tumorigenesis in a context-dependent manner, and
support the hypothesis that activation of FGFR3 signaling contributes to human cancer.
K-Ras and -catenin mutations cooperate with Fgfr3
mutations in mice to promote tumorigenesis in the skin
and lung, but not in the bladder
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We then bred UroIICre+ mice to lines carrying Fgfr3 K644E and
Fgfr3 K644M mutations (murine equivalent of human K652E and
K652M, respectively) (Iwata et al., 2000; Iwata et al., 2001). Both
of these mutations have been found in human UCC (Knowles,
2008a) and are known to highly activate the kinase activity of the
receptor (Iwata et al., 2001). Both lines carry a neomycin resistant
gene (neo) flanked by loxP sites in the intron prior to the exon with
the K644 mutation. This neo insertion is known to suppress the
expression of the Fgfr3 mutant allele in the absence of Cre
recombination. In the presence of Cre, the neo gene is excised,
allowing expression of the mutant Fgfr3 protein. In the offspring
(UroIICre+Fgfr3+/K644E and UroIICre+Fgfr3+/K644M), the pattern and
approximate levels of Fgfr3 protein expression were similar to those
of the age-matched wild-type mice (supplementary material Fig.
S1B,C,F).
Fgfr3 mutation alone does not drive tumorigenesis of the bladder
To investigate the role of Fgfr3 mutations as a driver of UCC, we
aged the UroIICre+Fgfr3+/K644E and UroIICre+Fgfr3+/K644M mutant
mice to 18 months (tumor phenotype is summarized in
supplementary material Table S1). Neither of these lines developed
urothelial hyperplasia, dysplasia or carcinoma (Fig. 1E,I). After 2
hours of in vivo incorporation of 5-bromo-2-deoxyuridine (BrdU),
no apparent positivity was observed, indicating that little or no cell
proliferation took place in the urothelium either in the wild-type
or in the mutant cohorts (Fig. 1F,J). We next examined some of the
well-known core signaling pathways downstream of FGF. A strong
upregulation of expression of phosphorylated extracellular-signal-
regulated kinases 1 and 2 (pERK1/2) was observed in both
UroIICre+Fgfr3+/K644E and UroIICre+Fgfr3+/K644M mutants
compared with wild type (Fig. 1G,K and supplementary material
Fig. S2). This was accompanied by an upregulation of Sprouty2
levels (Fig. 1H,L and supplementary material Fig. S2). No significant
pAKT(Ser473) or p-mTOR staining was present in the Fgfr3
mutant cohorts, similar to wild type (supplementary material Fig.
S3).
Next, we addressed whether Fgfr3 mutations require other
mutations for the formation of UCC. FGFR3 and H-RAS mutations
are reported to be mutually exclusive events in human UCC (Jebar
et al., 2005). Previous studies that have examined K-RAS mutations
in a mixture of human bladder cancer have suggested a wide
variation in frequency (4-29%) (Uchida et al., 1995; Olderoy et al.,
1998; Ayan et al., 2001). In order to address how much of the FGFR3
signaling activities are augmented by additional upregulation of the
ERK-MAPK pathway, we examined the role of oncogenic K-Ras
G12D (Jackson et al., 2001) in UroIICre+Fgfr3+/K644EK-RasG12D/+
mice (n23) (supplementary material Table S1). Upon aging to 12
months, no UroIICre+Fgfr3+/K644EK-RasG12D/+ mice developed
urothelial hyperplasia, dysplasia or carcinoma (Fig. 1M) and no
apparent changes in BrdU incorporation were observed (Fig. 1N).
Fig. 1. Fgfr3 mutation is not the sole
driver of tumorigenesis in the bladder.
The samples are from 12-month-old wild-
type (A-D), UroIICre+Fgfr3+/K644E (E-H),
UroIICre+Fgfr3+/K644M (I-L),
UroIICre+Fgfr3+/K644EK-RasG12D/+ (M-P) and
UroIICre+Fgfr3+/K644E-cateninexon3/+ (Q-T)
mice. Hematoxylin and eosin (H&E)
staining showed no apparent lesions in the
urothelium in all Fgfr3 mutants (A,E,I,M)
except for the compound model with -
cateninexon3/+ (Q), in which hyperplasia was
observed (red arrowhead; also in S,T). No
significant cell proliferation was observed
(B,F,J,N) except for the area of hyperplastic
lesion in UroIICre+Fgfr3+/K644E-cateninexon3/+
mice (black arrowhead) (R). Upregulation of
pERK1/2 (G,K,O,S) and Sprouty2 (H,L,P,T)
was observed in Fgfr3 mutant mice,
compared with wild type (C,D,
respectively). Scale bar: 200m.
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Similar to the single mutants, a strong upregulation of pERK1/2
(Fig. 1O) as well as an accompanying upregulation of Sprouty2 (Fig.
1P) was observed. Comparable levels of upregulation of pERK1/2
and Sprouty2 were observed in the UroIICre+K-RasG12D/+
urothelium (data not shown). Minimal levels of upregulation
of  pAKT(Ser473) and p-mTOR were observed in the
UroIICre+Fgfr3+/K644EK-RasG12D/+ cohorts (supplementary material
Fig. S3).
Mounting evidence is present for a role of Wnt pathway
activation in human bladder cancer development, including an
association between the accumulation of nuclear -catenin and
reduced patient survival (Kastritis et al., 2009). We recently reported
the first in vivo evidence of -catenin activation leading to the
formation of UCC when combined with other tumor suppressor
mutations, such as a loss of Pten (Ahmad et al., 2011a). In addition,
we have also shown that the -catenin mutation can cooperate with
H-Ras mutation to drive superficial bladder cancer (Ahmad et al.,
2011b). In order to test whether there is cooperation between the
FGF and Wnt pathways in bladder tumorigenesis, we examined
the role of -catenin activating mutations (Harada et al., 1999) in
UroIICre+Fgfr3+/K644E-cateninexon3/+ mice (n27) (supplementary
material Table S1).
In order to drive deregulated Wnt signaling, we used mice that
carry a dominant allele of the -catenin gene in which exon 3 is
flanked by loxP sequences (Harada et al., 1999). In these mice, Cre
recombinase deletes exon 3, which contains the residues that are
phosphorylated by GSK3. Thus, -catenin will accumulate in the
nucleus and drive Wnt signaling (Moon et al., 2004). Although areas
of hyperproliferation were observed in the bladders of
UroIICre+Fgfr3+/K644E-cateninexon3/+ mice from approximately 3
months of age in 100% of mice (n20), equivalent lesions were also
found in the UroIICre+-cateninexon3/+ urothelium (Ahmad et al.,
2011a). In both groups these lesions incorporated BrdU (Fig. 1R);
however, they never progressed further (examination up to 12
months) (Fig. 1Q). Once again, upregulation of pERK1/2 and
Sprouty2 was observed in this model (Fig. 1S,T). The areas of
hyperproliferation that were observed in UroIICre+-cateninexon3/+
mice showed comparable levels of upregulation of BrdU, pERK1/2
and Sprouty2 in the lesions (data not shown), indicating that Fgfr3
mutations are not contributing to urothelial hyperplasia in
UroIICre+Fgfr3+/K644E-cateninexon3/+ mice. No upregulation of
pAKT(Ser473) or p-mTOR was observed in this model
(supplementary material Fig. S3). Taken together, these data suggest
that K-Ras and -catenin activating mutations do not cooperate
with Fgfr3 mutation to drive UCC or to enhance signaling.
Skin papilloma formation in UroIICre+Fgfr3+/K644EK-RasG12D/+ mice
In contrast to observations in the urothelium, by 1 year of age, 44%
(9/23) of the UroIICre+Fgfr3+/K644EK-RasG12D/+ cohort developed
papilloma (Fig. 2A; supplementary material Table S1, Fig. S4). The
tumors reached 1 cm in diameter by a median of 220 days (mean
249 days). Upon crossing of the UroIICre+Fgfr3+/K644EK-RasG12D/+
mice to the Z/EG reporter line, a strong GFP signal was observed
within papillomas, indicating that the tumor formation was due to
sporadic Cre recombination in the tumor (Fig. 2G). By contrast,
no papilloma was observed in the UroIICre+K-RasG12D/+ cohort
aged up to 18 months (n20), indicating that Fgfr3 mutation
cooperates with K-Ras mutation to drive papilloma formation.
The papillomas in the UroIICre+Fgfr3+/K644EK-RasG12D/+ cohort
incorporated BrdU (Fig. 2B). In terms of signaling, tumor formation
was associated with a robust activation of pERK1/2 expression in
the absence of Sprouty2 upregulation (Fig. 2C,D). This is distinct
from the observation in the urothelium of these mice (Fig. 1P),
where Sprouty2 upregulation was seen (Fig. 2D), suggesting that
the negative feedback counteracting the oncogenic ERK-MAPK
pathway has not occurred in this line. Levels of pAKT(Ser473) and
p-mTOR were unchanged (Fig. 2E,F). We also compared the
signaling profiles observed in these papillomas of Fgfr3 mutants
with those of papillomas from UroIICre+K-RasG12D/+Ptenfl/+ mice,
which regularly develop papillomas (8/19; 42%) (supplementary
material Fig. S5A). We found a similar increase of BrdU
incorporation (supplementary material Fig. S5B). However, in
contrast to UroIICre+Fgfr3+/K644EK-RasG12D/+ papillomas, only mild
upregulation of nuclear and cytoplasmic pERK1/2 was observed
in the lesion, verified by the Histoscore quantification (n3, P<0.001
and 0.05, respectively) (supplementary material Fig. S5C,I,J).
Sprouty2 was also mildly upregulated (supplementary material Fig.
S5D). Furthermore, the ERK downstream effectors pElk and Pea3
Fig. 2. Formation of papilloma lesions in the UroIICre+Fgfr3+/K644EK-
RasG12D/+ model. Papilloma samples are from 12-month-old
UroIICre+Fgfr3+/K644EK-RasG12D/+ mice. H&E staining shows the formation of a
papilloma (A), in which BrdU immunoreactivity demonstrated cell proliferation
(B). Upregulation of pERK1/2 was observed (C), as was observed in the
urothelium (Fig. 1O). However, upregulation of Sprouty2 was not present in
UroIICre+Fgfr3+/K644EK-RasG12D/+ mice (D). Neither pAKT(Ser473) (E) nor p-mTOR
(F) was upregulated in papillomas formed in UroIICre+Fgfr3+/K644EK-RasG12D/+
mice. GFP imaging indicated Cre-recombined cells in the papilloma (G). 14
magnification was used. Scale bar: 200m in all panels except for G.
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were downregulated (supplementary material Fig. S5E,F), indicating
that overall ERK was not very high in this model. Conversely, we
found much higher levels of pAKT(Ser473) staining in papillomas
of the UroIICre+K-RasG12D/+Ptenfl/+ mice in comparison to
UroIICre+Fgfr3+/K644EK-RasG12D/+ mice (n3, P<0.001;
supplementary material Fig. S5G,H,K,L). 
Formation of lung tumors in UroIICre+Fgfr3+/K644E-cateninexon3/+
mice
Although there was no papilloma formation, 36% (10/27) of the
UroIICre+Fgfr3+/K644E-cateninexon3/+ mice developed lung tumors
by 1 year of age (supplementary material Table S1 and Fig. S4).
Imaging with the OV100 microscope showed a strong GFP signal
in the lung tumor, indicating that the tumor formation was due to
sporadic Cre recombination in the tumor (supplementary material
Fig. S6A). These tumors resembled most closely solitary fibrous
tumors (SFTs) of the lung (supplementary material Fig. S6B). SFTs
were mostly termed hemangiopericytomas (HPCs) in the past.
According to the World Health Organization (WHO), these tumors
are mesenchymal neoplasms of subendothelial origin that can be
found mostly in the pleura but also in extraserosal sites, such as
lung, mediastinum, liver, head and neck, and deep soft tissues of
the extremities. Most SFTs behave as slowly growing, painless
masses (Kouki et al., 2008). No lung tumors were observed in the
UroIICre+-cateninexon3/+ mice aged up to 18 months (n20;
supplementary material Table S1). Therefore, in this instance, Fgfr3
mutation cooperates with -catenin activation to drive lung
tumorigenesis. In these lung tumors formed in
UroIICre+Fgfr3+/K644E-cateninexon3/+ mice, strong BrdU positivity
indicated rapid cell proliferation (supplementary material Fig.
S6C). In addition, tumors showed high levels of nuclear -catenin,
consistent with the activation of -catenin owing to Cre-mediated
excision of exon 3 (supplementary material Fig. S6D). In humans,
nuclear -catenin is found in up to a third of SFTs (Yamaguchi et
al., 2004; Ng et al., 2005; Rakheja et al., 2005; Andino et al., 2006;
Carlson and Fletcher, 2007).
In terms of downstream signaling, increased levels of
pAKT(Ser473) and p-mTOR were observed (supplementary
material Fig. S6E,F), suggesting the involvement of the AKT
pathway in tumorigenesis. By contrast, we found minimal
upregulation of pERK1/2 and Sprouty2 (supplementary material
Fig. S6G,H).
We compared this phenotype with lung tumors found in
UroIICre+-cateninexon3/+K-RasG12D/+ mice (n17) (Ahmad et al.,
2011b). In these tumors, we found little upregulation of pAKT
(supplementary material Fig. S6I), but strong upregulation of
pERK1/2 with a corresponding fall in Sprouty2 expression
(supplementary material Fig. S6K,L). Upon quantification of the
staining intensity using a weighted Histoscore technique, we found
statistically significant increases in both nuclear and cytoplasmic
pERK1/2 staining in the UroIICre+-cateninexon3/+K-RasG12D/+
cohort compared with the UroIICre+Fgfr3+/K644E-cateninexon3/+
mice (n3, P<0.001; supplementary material Fig. S6M,N).
Conversely, we found much higher levels of pAKT(Ser473) staining
in lung tumors of the UroIICre+Fgfr3+/K644E-cateninexon3/+ mice in
comparison to UroIICre+-cateninexon3/+K-RasG12D/+ mice (n3,
P<0.001; supplementary material Fig. S6O,P). Consistent with this,
less p-mTOR staining was present in UroIICre+Fgfr3+/K644E-
cateninexon3/+ mice (supplementary material Fig. S6J).
Taken together, these results suggest that activation of the AKT
pathway might contribute to tumorigenesis in the lung of
UroIICre+Fgfr3+/K644E-cateninexon3/+ mice and papilloma of
UroIICre+K-RasG12D/+Ptenfl/+ mice. This differs to the signaling
observed in papillomas of UroIICre+Fgfr3+/K644EK-RasG12D/+ mice,
and in bladder tumors of UroIICre+H-RasQ61L and UroIICre+-
cateninexon3/exon3H-RasQ61L mice (Ahmad et al., 2011b), in which
elevation of the ERK-MAPK pathway might play a major role in
tumorigenesis. In summary, we hypothesize that there are two
independent pathways, activation of ERK-MAPK and that of AKT,
that could play a role in tumorigenesis in the presence of Fgfr3
mutations. This hypothesis is presented as a model in
supplementary material Fig. S7. 
Elevation of ERK downstream signaling is associated with tumor
formation in the bladder and in papilloma
Given the difficulty of assigning ERK pathway activity in vivo, we
next examined the expression of two known targets of ERK: Pea
and pELK (O’Hagan et al., 1996; Cruzalegui et al., 1999). In the
bladder of UroIICre+Fgfr3+/K644E mice, the levels of Pea3 and pElk1
were mildly upregulated (Fig. 3C,D) when compared with wild-
type bladders (Fig. 3A,B). By contrast, in papillomas from
UroIICre+Fgfr3+/K644EK-RasG12D/+ mice, Pea3 and pElk1 expression
was highly upregulated (Fig. 3E,F). Quantitative reverse-
transcriptase PCR (RT-PCR) experiments showed that, in
UroIICre+Fgfr3+/K644EK-RasG12D/+ papillomas (n2), the relative
expression level of the Pea3 transcript normalized by actin was
increased by 120-fold compared with that in wild-type bladders
(n4), with the average threshold cycle (Ct) values of 9.37 and
16.28±0.88 in papilloma and wild-type bladders, respectively. By
contrast, a difference in the expression levels of Pea3 between the
bladders of UroIICre+Fgfr3+/K644E (n3) and wild type was not
detected at the transcript level (average Ct  15.76±0.97 in
UroIICre+Fgfr3+/K644E; statistically not significant). This is in
accordance with our hypothesis that the upregulation of pERK1/2
in the absence of Sprouty2 leads to an overall increase in ERK
signaling in papillomas of UroIICre+Fgfr3+/K644EK-RasG12D/+ mice
(Fig. 2C,D). By contrast, we suggest that Sprouty2 upregulation is
sufficient to suppress the overall ERK signaling levels in the
bladders of UroIICre+Fgfr3+/K644E mice (Fig. 1G,H). We have also
examined Pea3 and pELK1 levels in two established bladder tumor
models, UroIICre+H-RasQ61L and UroIICre+-cateninexon3/exon3H-
RasQ61L (Ahmad et al., 2011b). In these models, both Pea3 and pElk1
levels are highly upregulated in the bladder tumors (Fig. 3G-J),
indicating that strong activation of the ERK-MAPK pathway might
be one of the pathways that drives bladder tumor formation.
Finally, we have examined the ERK-MAPK signaling pathway in
human UCC by using a tissue microarray (TMA) that contains 60
UCC and 20 benign controls (Folio Biosciences, OH). Using the
Histoscore technique, we have quantified the staining intensities
of pERK1/2, pElk1 and Sprouty2 (Fig. 4A). A significant correlation
was observed in the upregulation of pERK1/2 and that of pElk1
(Pearson correlation coefficient0.6082, P<0.0001, two-tailed)
(MiniTab v15) (Fig. 4B), indicating that an elevation of overall ERK
signaling is associated with human UCC. Furthermore, a significant
correlation was also observed between the upregulation of pERK1/2
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and the downregulation of Sprouty2 (Pearson correlation
coefficient0.6596, P<0.0001, two-tailed) (data not shown),
indicating that the absence of Sprouty2 upregulation might underlie
the mechanism leading to UCC formation in humans. In addition,
using Oncomine (https://www.oncomine.org), Lindgren and
colleagues demonstrated that, in FGFR3 mutant bladder cancer,
there is a downregulation of Sprouty2 at the mRNA level (P0.015)
(Lindgren et al., 2006). In the same study, Sprouty2 mRNA levels
were found to be downregulated as the disease progresses from
Grade 1 to 3 (P0.015).
DISCUSSION
We demonstrate here that activating mutations of FGFR3 are
unlikely to be the sole initiating factor for UCC and that neither
-cateninexon3/+ nor K-RasG12D/+ mutation cooperates with FGFR3
to drive UCC. FGFR3 mutations are thought to be mutually
exclusive with H-RAS mutation (Jebar et al., 2005), and FGFR3 is
only rarely mutated with p53 (<5%) (Bakkar et al., 2003). Therefore,
generation of mouse models that recapitulate superficial UCCs that
have FGFR3 mutations might be difficult and will require greater
knowledge of the genetic changes that accompany FGFR3
mutations (Jebar et al., 2005; Wu, 2005; Puzio-Kuter et al., 2009).
The study, however, showed that somatic Fgfr3 mutations caused
a modest upregulation of the ERK-MAPK pathway in the
urothelium, which was accompanied by upregulation of Sprouty2,
one of the feedback inhibitors of the ERK-MAPK pathway (Fig. 1).
We speculate that upregulation of negative-feedback genes, such
as Sprouty2, could be one of the mechanisms by which UCC is
normally prevented. In papillomas in UroIICRE+Fgfr3+/K644EK-
RasG12D/+ mice, no concomitant upregulation of Sprouty2 had
occurred, potentially leading to uncontrolled activation of the ERK-
MAPK pathway in the absence of a negative-feedback mechanism
(Fig. 2). In the case of lung tumors in the UroIICre+Fgfr3+/K644E-
cateninexon3/+ cohort, a strong upregulation of the PI3K-pAKT and
Wnt–-catenin pathways might underlie tumorigenesis
(supplementary material Fig. S6). It is tempting to propose that
these differential downstream signaling profiles are the underlying
drivers of tumorigenesis, with the different oncogenic mutations
cooperating with FGFR3 mutation in a context-dependent fashion
(supplementary material Fig. S7). It would be interesting to assess
in the future whether downregulation of Sprouty2 in our mouse
system results in UCC formation. Tissue-specific effects of Fgfr3
Fig. 3. Elevation of ERK downstream signaling is associated with tumor
formation in the bladder and in papilloma formation. Activation of overall
ERK-MAPK signaling was examined in the bladders of wild-type (A,B) and
UroIICre+Fgfr3+/K644E (C,D) mice, in papilloma of UroIICre+Fgfr3+/K644EK-RasG12D/+
mice (E,F), and in bladder tumors of UroIICre+H-RasQ61L (G,H) and UroIICre+-
cateninexon3/exon3H-RasQ61L (I,J) mice by assessing expression of Pea3 (A,C,E,G,I)
and pElk1 (B,D,F,H,J). Upregulation of both Pea3 and pElk1 was observed in the
bladder of UroIICre+Fgfr3+/K644E mice compared with that of wild-type, and
further upregulation was observed in papilloma of UroIICre+Fgfr3+/K644EK-
RasG12D/+ mice, as well as in bladder tumor models with H-RasQ61L mutation.
Scale bar: 200m.
Fig. 4. Correlation between pERK1/2 and downstream effectors in human
UCC TMA. The downstream signaling of the ERK-MAPK pathway was
examined using a commercially available TMA containing 60 UCC and 20
benign bladder tumors. (A)An example of UCC samples, showing strong
immunohistochemical staining of pERK1/2 and pElk1, and a weak staining of
Sprouty2. Each core size is 1.5 mm in diameter. (B)Scatterplot demonstrating a
correlation between the upregulation of pERK1/2 with that of pElk1. 
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mutation could also be caused by differential kinetics of Fgfr3
protein turnover in the bladder, skin and lung. Such a possibility
could be tested by the generation of a mouse model that allows
expression of a tagged Fgfr3 protein.
Fgfr3 K652E and K652M mutations, which we described here,
are found in human UCC but are much less frequent (3%) than
the S249C mutation, which accounts for 67% of the FGFR3
mutations in bladder cancer (Knowles, 2008a). Thus, it is possible
that S249C mutation is more oncogenic in the bladder than are
K652E or K652M. In vitro, both S249C and K652E or K653M
mutations are shown to constitutively increase the FGFR3 kinase
activity, albeit with different mechanisms (Naski et al., 1996; d’Avis
et al., 1998). S249C is known to cause ligand-independent
dimerization, whereas K652E or K652M promotes a
conformational change that favors autophosphorylation, and its
kinase activity can be further enhanced by additional ligand
stimulation (Naski et al., 1996; d’Avis et al., 1998). Upon measuring
transcription-inducing activity by the fos-luciferase reporter assay,
K644E mutant protein was found to be twice as active as S249C
mutant in the absence of ligand (d’Avis et al., 1998). Preliminary
data suggest that transgenic mice with a human FGFR3IIIb isoform
with S249C mutation did not show any tumors in the bladder up
to 1 year of age (Margaret Knowles, Leeds Institute for Molecular
Medicine, UK, personal communication).
The skin papilloma and lung tumors observed in our study with
Fgfr3 mutations are relevant in human cancers (Woenckhaus et al.,
2006; Hafner et al., 2007; Cortese et al., 2008). Overexpression of
the FGFR3 S249C mutation from the K5 promoter in transgenic
mice resulted in the formation of a benign skin tumor (Logie et al.,
2005). Our study is consistent with this previous report.
Recent work has elegantly demonstrated that knockdown of
FGFR3 expression suppresses the growth of bladder cell lines and
mouse xenograft models of bladder cancer (Qing et al., 2009).
Furthermore, FGFR3-specific monoclonal antibody (R3Mab)
significantly inhibits growth and progression of xenograft tumors
that harbor the S249C and K650E mutations (Qing et al., 2009).
Further studies of the FGFR3 signaling pathway, which is frequently
deregulated in UCC, is therefore essential, firstly to allow one to
stratify patients according to risk of progression and/or recurrence,
and secondly to aid in patient selection for either the single agent
or combination therapy with small-molecule- and monoclonal-
antibody-based treatments in the future (Black et al., 2007; Knowles,
2008a; Qing et al., 2009). Moreover, identifying the cooperating
molecular events that occur alongside FGFR3 mutation to drive
UCC will aid the development of genetic models of UCC to test
combinatorial therapies.
METHODS
Mice
Uroplakin II Cre mice (UroIICre+) (Zhang et al., 1999) were
intercrossed with mice harboring Fgfr3 K644E and Fgfr3 K644M
(Fgfr3+/K644Eneo and Fgfr3+/K644Mneo) (Iwata et al., 2000; Iwata et al.,
2001), -cateninexon3/+ (Harada et al., 1999), and K-RasG12D/+
(Jackson et al., 2001) mutations. Mice were genotyped by PCR as
previously described (Harada et al., 1999; Zhang et al., 1999; Iwata
et al., 2000; Iwata et al., 2001; Jackson et al., 2001). Mice were of a
mixed background and littermates were used as control mice. All
experiments were carried out in accordance with the Project
Licence under Home Office Animal (Scientific Procedures) Act
1986 in the UK.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on formalin-fixed,
paraffin-embedded samples. Upon harvesting, the bladders were
emptied of urine before being placed in formalin for overnight
fixation and were paraffin embedded. All bladders were processed
and cut in the same manner by a single histology technician to aid
standardization. For each genotype we stained at least three
samples from different mice and took representative images. We
used antibodies against: FGFR3 (C-15, Santa Cruz Biotechnology,
1:20, no antigen retrieval), BrdU (347580, BD Biosciences, 1:500,
citrate buffer and microwave antigen retrieval), pERK1/2 (#9101,
Cell Signaling, 1:100, citrate buffer and microwave antigen
retrieval), Sprouty2 (ab60719, AbCam, 1:300, citrate buffer and
microwave antigen retrieval), pAKT(Ser473) (#3787, Cell Signaling,
1:50, citrate buffer and microwave antigen retrieval), -catenin
TRANSLATIONAL IMPACT
Clinical issue
Urothelial cell carcinoma (UCC) of the bladder is the fifth most common cancer
worldwide. Because bladder cancer has a tendency to recur even in the non-
invasive cases, it is one of the most expensive and labor-intensive cancers to
manage. Fibroblast growth factor receptor 3 (FGFR3) is a receptor tyrosine
kinase that is known to mediate the effects of fibroblast growth factors (FGFs).
Several studies have shown that mutations in FGFR3 are closely associated
with bladder cancer of a low tumor grade and stage. However, whether and
how FGFR3 mutations contribute to bladder tumorigenesis is unknown. Thus,
generation of a relevant mouse model is essential not only for investigating
this issue but also for testing potential therapeutic approaches. 
Results
In this paper, the authors test the capacity of FGFR3 activating mutations to
drive UCC by creating a mouse model in which mutated Fgfr3 is targeted to
the urothelium, using Cre-loxP recombination driven by a urothelium-specific
promoter. Their findings demonstrate that activating mutations in FGFR3 are
unlikely to be the sole initiating factor for UCC, even in the presence of
activating mutations in K-Ras or -catenin. However, sporadic ectopic Cre
recombinase expression in the skin and lung of these mice shows that an Fgfr3
activating mutation can cause papillomas (by cooperating with K-Ras) and
promote lung tumorigenesis (by cooperating with -catenin). Furthermore,
somatic Fgfr3 mutations cause upregulation of the ERK-MAPK pathway, as well
as upregulation of Sprouty2 (a feedback inhibitor of the pathway) in the
urothelium, but do not lead to UCC formation. By contrast, the formation of
papillomas in mice carrying activating mutations in both Fgfr3 and K-Ras were
not associated with upregulation of Sprouty2, potentially leading to
uncontrolled activation of the ERK-MAPK pathway in these mice. Therefore, the
authors speculate that feedback inhibitors of the FGF signaling pathway might
be one of the mechanisms by which UCC is normally prevented. 
Implications and future directions
These data indicate that activating mutations in FGFR3 can cooperate with
other mutations to drive tumorigenesis in a context-dependent manner.
However, further studies of how the FGFR3 signaling pathway is dysregulated
in UCC are required to enable patient stratification according to risk of
progression and recurrence, and to aid in patient selection for single-agent or
combination therapies. Moreover, identifying molecular events that cooperate
with FGFR3 activating mutations to drive UCC formation will aid in the
development of genetic models of UCC to test these therapies.
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(C19220, Transduction Labs, 1:50, Tris/EDTA water bath antigen
retrieval with 50 minutes at 99°C), p-mTOR(Ser2448) (#2976, Cell
Signaling, 1:100, citrate buffer and microwave antigen retrieval),
pElk1(Ser389) (ab28818, Abcam, 1:50, citrate buffer and microwave
antigen retrieval) and Pea3 (ab70425, Abcam, 1:200, citrate buffer
and microwave antigen retrieval).
Quantification of IHC staining
For each tissue section (n5), the percentage of positive
immunoreactivity in the nucleus and cytoplasm was evaluated with
40 magnification objectives. Staining intensity was categorized
into three categories: 0, 1, 2 or 3, denoting negative, weak, moderate
or strong staining, respectively. The final Histoscore was calculated
from the sum of (1  % weakly positive tumor cells) + (2  %
moderately positive tumor cells) + (3  % strongly positive tumor
cells), with a maximum Histoscore of 300 (Kirkegaard et al., 2006).
Statistics were performed using the Student’s t-test (Minitab).
Human TMA
The TMA (Folio Biosciences, OH) consisted of 60 UCC and 20
benign bladder cores with data that consisted of patient sex, age
and tumor grade. Slides were scanned using the Aperio slide
scanner.
RNA isolation and quantitative RT-PCR
Bladders and papilloma tissues were collected in RNAlater RNA
stabilization reagent and RNA was isolated using the RNeasy Mini
Kit (Qiagen). DNase digest was performed using the DNAfree Kit
(Ambion). Reverse transcription was carried out using the
SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen).
Finally, quantitative PCR was carried out using DyNAmo SYBR
Green qPCR Kit (Finnzymes) on a Chromo4 Real-Time PCR cycler
(BioRad). PCR primers for actin and Pea3 were obtained from
Qiagen (Quantitect qPCR Primer Assay).
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